Meeting
2017 ASCO Annual Meeting
Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.
Authors
Jonathan A. Ledermann
University College London Cancer Institute, London, United Kingdom
Jonathan A. Ledermann , Alain Lortholary , Richard T. Penson , Emma Gibbs , Diane M. Provencher , Ilan Bruchim , Tomas Huzarski , Maria Pilar Barretina-Ginesta , Roberto Sabbatini , Linda R. Mileshkin , Nicoletta Colombo , Tjoung-Won Park-Simon , Koji Matsumoto , Gabe S. Sonke , Olga N. Mikheeva , Jae-Weon Kim , Gustavo Colagiovanni Girotto , Hannelore Denys , Elizabeth S. Lowe , Eric Pujade-Lauraine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01874353
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5518)
DOI
10.1200/JCO.2017.35.15_suppl.5518
Abstract #
5518
Poster Bd #
340
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Frequency, severity and timing of common adverse events (AEs) with maintenance olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).
First Author: Ursula Matulonis
Poster
2023 ASCO Annual Meeting
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
First Author: Philipp Harter
Poster
2022 ASCO Annual Meeting
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.
First Author: Sandro Pignata
Poster
2020 ASCO Virtual Scientific Program
Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.
First Author: Andres Poveda